Literature DB >> 26637742

Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?

Eric Padron1.   

Abstract

The myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) lie at the interphase of phenotypically opposing bone marrow malignancies. They are characterized by concomitant features of bone marrow failure and myeloproliferation and are generally associated with a poor prognosis. Although much is unknown with respect to the clinical course and molecular biology of MDS/MPNs, emerging research is beginning to uncover the key defining characteristics of this designation. In this review, we will discuss the features of MDS/MPN diseases that unify there clinical and molecular course and those that define distinct disease entities. We will discuss advances in genetics and MDS/MPN modeling, as well as translational discoveries that are anticipated to inform the diagnosis, prognostication, and treatment of MDS/MPNs in the near future.
© 2015 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26637742     DOI: 10.1182/asheducation-2015.1.349

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  3 in total

1.  Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm.

Authors:  Pingnan Xiao; Monika Dolinska; Lakshmi Sandhow; Makoto Kondo; Anne-Sofie Johansson; Thibault Bouderlique; Ying Zhao; Xidan Li; Marios Dimitriou; George Z Rassidakis; Eva Hellström-Lindberg; Nagahiro Minato; Julian Walfridsson; David T Scadden; Mikael Sigvardsson; Hong Qian
Journal:  Blood Adv       Date:  2018-03-13

2.  Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Authors:  Joseph A Clara; David A Sallman; Eric Padron
Journal:  Cancer Biol Med       Date:  2016-09       Impact factor: 4.248

3.  Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia.

Authors:  Leo Reap; Lyle Goldman
Journal:  Leuk Res Rep       Date:  2020-10-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.